Gazdar Adi F, Savage Trisha K, Johnson Jane E, Berns Anton, Sage Julien, Linnoila R Ilona, MacPherson David, McFadden David G, Farago Anna, Jacks Tyler, Travis William D, Brambilla Elisabeth
*Hamon Center for Therapeutic Oncology Research and Department of Pathology, UT Southwestern Medical Center, Dallas, TX; †Department of Neuroscience, UT Southwestern Medical Center, Dallas, TX; ‡Cancer Genomics Centre, The Netherlands Cancer Institute, Amsterdam, The Netherlands; §Departments of Pediatrics and Genetics, Stanford University, Stanford, CA; ‖Center for Cancer Research, National Cancer Institute, Bethesda, MD; ¶Division of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA; #David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02142; **Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY; and ††Departementd'Anatomie et Cytologie Pathologiques, INSERM Unit 823, Centre Hospitalier Universitaire Albert Michallon, and Institut Albert Bonniot University, Grenoble, France.
J Thorac Oncol. 2015 Apr;10(4):553-64. doi: 10.1097/JTO.0000000000000459.
Because small-cell lung carcinomas (SCLC) are seldom resected, human materials for study are limited. Thus, genetically engineered mouse models (GEMMs) for SCLC and other high-grade lung neuroendocrine (NE) carcinomas are crucial for translational research.
The pathologies of five GEMMs were studied in detail and consensus diagnoses reached by four lung cancer pathology experts. Hematoxylin and Eosin and immunostained slides of over 100 mice were obtained from the originating and other laboratories and digitalized. The GEMMs included the original Rb/p53 double knockout (Berns Laboratory) and triple knockouts from the Sage, MacPherson, and Jacks laboratories (double knockout model plus loss of p130 [Sage laboratory] or loss of Pten [MacPherson and Jacks laboratories]). In addition, a GEMM with constitutive co-expression of SV40 large T antigen and Ascl1 under the Scgb1a1 promoter from the Linnoila laboratory were included.
The lung tumors in all of the models had common as well as distinct pathological features. All three conditional knockout models resulted in multiple pulmonary tumors arising mainly from the central compartment (large bronchi) with foci of in situ carcinoma and NE cell hyperplasia. They consisted of inter- and intra-tumor mixtures of SCLC and large-cell NE cell carcinoma in varying proportions. Occasional adeno- or large-cell carcinomas were also seen. Extensive vascular and lymphatic invasion and metastases to the mediastinum and liver were noted, mainly of SCLC histology. In the Rb/p53/Pten triple knockout model from the MacPherson and Jacks laboratories and in the constitutive SV40/T antigen model many peripherally arising non-small-cell lung carcinoma tumors having varying degrees of NE marker expression were present (non-small-cell lung carcinoma-NE tumors). The resultant histological phenotypes were influenced by the introduction of specific genetic alterations, by inactivation of one or both alleles of specific genes, by time from Cre activation and by targeting of lung cells or NE cell subpopulations.
The five GEMM models studied are representative for the entire spectrum of human high-grade NE carcinomas and are also useful for the study of multistage pathogenesis and the metastatic properties of these tumors. They represent one of the most advanced forms of currently available GEMM models for the study of human cancer.
由于小细胞肺癌(SCLC)很少进行手术切除,用于研究的人体材料有限。因此,用于SCLC和其他高级别肺神经内分泌(NE)癌的基因工程小鼠模型(GEMM)对于转化研究至关重要。
详细研究了五种GEMM的病理情况,并由四位肺癌病理专家达成共识诊断。从原始实验室和其他实验室获取了100多只小鼠的苏木精和伊红染色以及免疫染色切片,并进行数字化处理。这些GEMM包括原始的Rb/p53双敲除模型(伯恩斯实验室)以及来自塞奇、麦克弗森和杰克斯实验室的三敲除模型(双敲除模型加上p130缺失[塞奇实验室]或Pten缺失[麦克弗森和杰克斯实验室])。此外,还包括来自利诺伊拉实验室的在Scgb1a1启动子控制下组成性共表达SV40大T抗原和Ascl1的GEMM。
所有模型中的肺肿瘤都有共同的以及独特的病理特征。所有三个条件性敲除模型都导致多个肺肿瘤主要起源于中央区域(大气道),伴有原位癌灶和NE细胞增生。它们由不同比例的SCLC和大细胞NE细胞癌的肿瘤内和肿瘤间混合物组成。偶尔也可见腺癌或大细胞癌。注意到广泛的血管和淋巴管侵犯以及转移至纵隔和肝脏,主要为SCLC组织学类型。在麦克弗森和杰克斯实验室的Rb/p53/Pten三敲除模型以及组成性SV40/T抗原模型中,存在许多外周起源的具有不同程度NE标志物表达的非小细胞肺癌肿瘤(非小细胞肺癌-NE肿瘤)。所产生的组织学表型受特定基因改变的引入、特定基因一个或两个等位基因的失活、Cre激活后的时间以及肺细胞或NE细胞亚群的靶向作用影响。
所研究的五个GEMM模型代表了人类高级别NE癌的整个谱系,也可用于研究这些肿瘤的多阶段发病机制和转移特性。它们代表了目前用于人类癌症研究的GEMM模型中最先进的形式之一。